CENTRAL DISTRICT, Hong Kong
- Dec. 16, 2020
-- 1Globe Biomedical's Indian venture will focus on stem cell research and therapies and also research into pharmaceutical remedies for certain types of diseases.
1Globe Biomedical's Chief Financial Officer commented on the Indian investment saying "This massive window of opportunity in India foe us and it will strengthen our super regional strategy and expand our ability to deliver top class medical research to developing countries."
1Globe Biomedical's Chief Financial Officer also added "The facility will be based in Bangalore with the most modern resources. India is the world's third largest economy and it remains one of the fastest growing economies in the world. Half of the world's generic medicine is manufactured in India so the potential is huge."
About Us - 1Globe Biomedical
1Globe Biomedical is a clinical stage biotechnology company pioneering the development of receptor T (1BioCARs™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of "off-the-shelf"
receptor T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.http://1globe-biomedical.com/about-us/history/index.html